Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma

Mengjun Wang, Ronald E. Long, Mary Ann Comunale, Omer Junaidi, Jorge Marrero, Adrian M. Di Bisceglie, Timothy M. Block, Anand S. Mehta

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Changes in glycosylation, most notably fucosylation, have been associated with the development of hepatocellular carcinoma (HCC). In this report, the levels of fucosylated kininogen (Fc-Kin) and fucosylated β-1-antitrypsin were analyzed individually and in combination with the currently used marker, α-fetoprotein, and a previously identified biomarker, Golgi protein 73 (GP73), for the ability to distinguish between a diagnosis of cirrhosis and HCC. This analysis was done on serum from 113 patients with cirrhosis and 164 serum samples from patients with cirrhosis plus HCC. The levels of Fc-Kin and fucosylated α-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, α-fetoprotein, and GP73, giving an optimal sensitivity of 95%, a specificity of 70%, and an area under the receiver operating characteristic of 0.94. In conclusion, the altered glycosylation of serum glycoproteins can act as potential biomarkers of primary HCC when used independently or in combination with other markers of HCC.

Original languageEnglish (US)
Pages (from-to)1914-1921
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Hepatocellular Carcinoma
Biomarkers
Kininogens
Fibrosis
Fetal Proteins
Glycosylation
Serum
ROC Curve
Glycoproteins
Proteins

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. / Wang, Mengjun; Long, Ronald E.; Comunale, Mary Ann; Junaidi, Omer; Marrero, Jorge; Di Bisceglie, Adrian M.; Block, Timothy M.; Mehta, Anand S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 6, 06.2009, p. 1914-1921.

Research output: Contribution to journalArticle

Wang, M, Long, RE, Comunale, MA, Junaidi, O, Marrero, J, Di Bisceglie, AM, Block, TM & Mehta, AS 2009, 'Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma', Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 6, pp. 1914-1921. https://doi.org/10.1158/1055-9965.EPI-08-0980
Wang, Mengjun ; Long, Ronald E. ; Comunale, Mary Ann ; Junaidi, Omer ; Marrero, Jorge ; Di Bisceglie, Adrian M. ; Block, Timothy M. ; Mehta, Anand S. / Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 6. pp. 1914-1921.
@article{433144fb20654409b4b4dbcc6ff08688,
title = "Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma",
abstract = "Changes in glycosylation, most notably fucosylation, have been associated with the development of hepatocellular carcinoma (HCC). In this report, the levels of fucosylated kininogen (Fc-Kin) and fucosylated β-1-antitrypsin were analyzed individually and in combination with the currently used marker, α-fetoprotein, and a previously identified biomarker, Golgi protein 73 (GP73), for the ability to distinguish between a diagnosis of cirrhosis and HCC. This analysis was done on serum from 113 patients with cirrhosis and 164 serum samples from patients with cirrhosis plus HCC. The levels of Fc-Kin and fucosylated α-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, α-fetoprotein, and GP73, giving an optimal sensitivity of 95{\%}, a specificity of 70{\%}, and an area under the receiver operating characteristic of 0.94. In conclusion, the altered glycosylation of serum glycoproteins can act as potential biomarkers of primary HCC when used independently or in combination with other markers of HCC.",
author = "Mengjun Wang and Long, {Ronald E.} and Comunale, {Mary Ann} and Omer Junaidi and Jorge Marrero and {Di Bisceglie}, {Adrian M.} and Block, {Timothy M.} and Mehta, {Anand S.}",
year = "2009",
month = "6",
doi = "10.1158/1055-9965.EPI-08-0980",
language = "English (US)",
volume = "18",
pages = "1914--1921",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma

AU - Wang, Mengjun

AU - Long, Ronald E.

AU - Comunale, Mary Ann

AU - Junaidi, Omer

AU - Marrero, Jorge

AU - Di Bisceglie, Adrian M.

AU - Block, Timothy M.

AU - Mehta, Anand S.

PY - 2009/6

Y1 - 2009/6

N2 - Changes in glycosylation, most notably fucosylation, have been associated with the development of hepatocellular carcinoma (HCC). In this report, the levels of fucosylated kininogen (Fc-Kin) and fucosylated β-1-antitrypsin were analyzed individually and in combination with the currently used marker, α-fetoprotein, and a previously identified biomarker, Golgi protein 73 (GP73), for the ability to distinguish between a diagnosis of cirrhosis and HCC. This analysis was done on serum from 113 patients with cirrhosis and 164 serum samples from patients with cirrhosis plus HCC. The levels of Fc-Kin and fucosylated α-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, α-fetoprotein, and GP73, giving an optimal sensitivity of 95%, a specificity of 70%, and an area under the receiver operating characteristic of 0.94. In conclusion, the altered glycosylation of serum glycoproteins can act as potential biomarkers of primary HCC when used independently or in combination with other markers of HCC.

AB - Changes in glycosylation, most notably fucosylation, have been associated with the development of hepatocellular carcinoma (HCC). In this report, the levels of fucosylated kininogen (Fc-Kin) and fucosylated β-1-antitrypsin were analyzed individually and in combination with the currently used marker, α-fetoprotein, and a previously identified biomarker, Golgi protein 73 (GP73), for the ability to distinguish between a diagnosis of cirrhosis and HCC. This analysis was done on serum from 113 patients with cirrhosis and 164 serum samples from patients with cirrhosis plus HCC. The levels of Fc-Kin and fucosylated α-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, α-fetoprotein, and GP73, giving an optimal sensitivity of 95%, a specificity of 70%, and an area under the receiver operating characteristic of 0.94. In conclusion, the altered glycosylation of serum glycoproteins can act as potential biomarkers of primary HCC when used independently or in combination with other markers of HCC.

UR - http://www.scopus.com/inward/record.url?scp=67449107963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449107963&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0980

DO - 10.1158/1055-9965.EPI-08-0980

M3 - Article

C2 - 19454616

AN - SCOPUS:67449107963

VL - 18

SP - 1914

EP - 1921

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -